The Effect of Pioglitazone on Nitric Oxide Synthase in Patients With Type 2 Diabetes Mellitus

Kazuaki Nishio MD, PhD, Meiei Shigemitsu MD, Yusuke Kodama MD, Seiji Itoh MD, Noburu Konno MD, PhD, Ryuji Satoh MD, Takashi Katagiri MD, PhD, Youichi Kobayashi MD, PhD
{"title":"The Effect of Pioglitazone on Nitric Oxide Synthase in Patients With Type 2 Diabetes Mellitus","authors":"Kazuaki Nishio MD, PhD,&nbsp;Meiei Shigemitsu MD,&nbsp;Yusuke Kodama MD,&nbsp;Seiji Itoh MD,&nbsp;Noburu Konno MD, PhD,&nbsp;Ryuji Satoh MD,&nbsp;Takashi Katagiri MD, PhD,&nbsp;Youichi Kobayashi MD, PhD","doi":"10.1111/j.1559-4572.2008.00019.x","DOIUrl":null,"url":null,"abstract":"<p>The aim of this study was to evaluate the effect of pioglitazone on nitric oxide in patients with type 2 diabetes and coronary artery disease. Twenty-seven patients with coronary artery disease and diabetes mellitus who had received coronary stenting were eligible for the study. They were assigned to the no insulin resistance (NIR) group, the insulin resistance (IR) group, and the pioglitazone group (30 mg once a day). Endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), tumor necrosis factor α (TNF-α), interleukin-6, leptin, and adiponectin were measured. In the pioglitazone group, eNOS, iNOS, and leptin were significantly lower and adiponectin was significantly higher than those in the IR group. Stepwise multiple regression analyses showed that eNOS correlated with TNF-α and iNOS correlated with leptin and TNF-α. Leptin was the strongest predictor of iNOS. Treatment with pioglitazone significantly reduced eNOS and iNOS by improving adipocytokine levels.</p>","PeriodicalId":87477,"journal":{"name":"Journal of the cardiometabolic syndrome","volume":"3 4","pages":"200-204"},"PeriodicalIF":0.0000,"publicationDate":"2008-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1559-4572.2008.00019.x","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the cardiometabolic syndrome","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1559-4572.2008.00019.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

Abstract

The aim of this study was to evaluate the effect of pioglitazone on nitric oxide in patients with type 2 diabetes and coronary artery disease. Twenty-seven patients with coronary artery disease and diabetes mellitus who had received coronary stenting were eligible for the study. They were assigned to the no insulin resistance (NIR) group, the insulin resistance (IR) group, and the pioglitazone group (30 mg once a day). Endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), tumor necrosis factor α (TNF-α), interleukin-6, leptin, and adiponectin were measured. In the pioglitazone group, eNOS, iNOS, and leptin were significantly lower and adiponectin was significantly higher than those in the IR group. Stepwise multiple regression analyses showed that eNOS correlated with TNF-α and iNOS correlated with leptin and TNF-α. Leptin was the strongest predictor of iNOS. Treatment with pioglitazone significantly reduced eNOS and iNOS by improving adipocytokine levels.

吡格列酮对2型糖尿病患者一氧化氮合酶的影响
本研究的目的是评估吡格列酮对2型糖尿病合并冠状动脉疾病患者一氧化氮的影响。27例接受冠状动脉支架植入术的冠心病和糖尿病患者符合研究条件。他们被分为无胰岛素抵抗(NIR)组、胰岛素抵抗(IR)组和吡格列酮组(30 mg,每天1次)。测定内皮型一氧化氮合酶(eNOS)、诱导型一氧化氮合酶(iNOS)、肿瘤坏死因子α (TNF-α)、白细胞介素-6、瘦素、脂联素。吡格列酮组eNOS、iNOS、leptin显著低于IR组,脂联素显著高于IR组。逐步多元回归分析显示,eNOS与TNF-α相关,iNOS与瘦素和TNF-α相关。瘦素是iNOS最强的预测因子。吡格列酮治疗通过提高脂肪细胞因子水平显著降低eNOS和iNOS。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信